

Hawre J Jalal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6331300/publications.pdf>

Version: 2024-02-01

38
papers

1,280
citations

471509

17
h-index

377865

34
g-index

44
all docs

44
docs citations

44
times ranked

1780
citing authors

#	ARTICLE	IF	CITATIONS
1	An Introductory Tutorial on Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example. <i>Medical Decision Making</i> , 2023, 43, 3-20.	2.4	8
2	Reply commentary by Jalal and Burke. <i>International Journal of Drug Policy</i> , 2022, , 103674.	3.3	1
3	Exponential growth of drug overdose poisoning and opportunities for intervention. <i>Addiction</i> , 2022, 117, 1200-1202.	3.3	5
4	Estimating the Impact of Low Influenza Activity in 2020 on Population Immunity and Future Influenza Seasons in the United States. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab607.	0.9	17
5	APCtools: Descriptive and Model-based Age-Period-Cohort Analysis. <i>Journal of Open Source Software</i> , 2022, 7, 4056.	4.6	1
6	Future projection of the health and functional status of older people in Japan: A multistate transition microsimulation model with repeated cross-sectional data. <i>Health Economics (United Kingdom)</i> , 2021, 30, 30-51.	1.7	6
7	How simulation modeling can support the public health response to the opioid crisis in North America: Setting priorities and assessing value. <i>International Journal of Drug Policy</i> , 2021, 88, 102726.	3.3	5
8	Microsimulation Model to Compare Enteral and Parenteral Iron Supplementation in Children With Intestinal Failure. <i>Journal of Parenteral and Enteral Nutrition</i> , 2021, 45, 810-817.	2.6	2
9	Carfentanil and the rise and fall of overdose deaths in the United States. <i>Addiction</i> , 2021, 116, 1593-1599.	3.3	35
10	Data Needs in Opioid Systems Modeling: Challenges and Future Directions. <i>American Journal of Preventive Medicine</i> , 2021, 60, e95-e105.	3.0	15
11	BayCANN: Streamlining Bayesian Calibration With Artificial Neural Network Metamodeling. <i>Frontiers in Physiology</i> , 2021, 12, 662314.	2.8	8
12	Is further research on adult pneumococcal vaccine uptake improvement programs worthwhile? \hat{I}^* value of information analysis. <i>Vaccine</i> , 2021, 39, 3608-3613.	3.8	1
13	Associations Between the Specialty of Opioid Prescribers and Opioid Addiction, Misuse, and Overdose Outcomes. <i>Pain Medicine</i> , 2020, 21, 1871-1890.	1.9	2
14	Computing PROPr Utility Scores for PROMIS [®] Profile Instruments. <i>Value in Health</i> , 2020, 23, 370-378.	0.3	33
15	Prioritizing Additional Data Collection to Reduce Decision Uncertainty in the HIV/AIDS Response in 6 US Cities: A Value of Information Analysis. <i>Value in Health</i> , 2020, 23, 1534-1542.	0.3	3
16	Hexamaps for Age-Period-Cohort Data Visualization and Implementation in R. <i>Epidemiology</i> , 2020, 31, e47-e49.	2.7	11
17	Dissemination Science to Advance the Use of Simulation Modeling: Our Obligation Moving Forward. <i>Medical Decision Making</i> , 2020, 40, 718-721.	2.4	4
18	Developing and Validating Metamodels of a Microsimulation Model of Infant HIV Testing and Screening Strategies Used in a Decision Support Tool for Health Policy Makers. <i>MDM Policy and Practice</i> , 2020, 5, 238146832093289.	0.9	6

#	ARTICLE	IF	CITATIONS
19	Age and generational patterns of overdose death risk from opioids and other drugs. <i>Nature Medicine</i> , 2020, 26, 699-704.	30.7	37
20	Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods. <i>Value in Health</i> , 2020, 23, 734-742.	0.3	51
21	A Multidimensional Array Representation of State-Transition Model Dynamics. <i>Medical Decision Making</i> , 2020, 40, 242-248.	2.4	6
22	Calculating the Expected Value of Sample Information in Practice: Considerations from 3 Case Studies. <i>Medical Decision Making</i> , 2020, 40, 314-326.	2.4	28
23	A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling. <i>Pharmacoeconomics</i> , 2019, 37, 1329-1339.	3.3	28
24	“Time Traveling Is Just Too Dangerous” but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier. <i>Value in Health</i> , 2019, 22, 611-618.	0.3	22
25	The Curve of Optimal Sample Size (COSS): A Graphical Representation of the Optimal Sample Size from a Value of Information Analysis. <i>Pharmacoeconomics</i> , 2019, 37, 871-877.	3.3	6
26	Microsimulation Modeling for Health Decision Sciences Using R: A Tutorial. <i>Medical Decision Making</i> , 2018, 38, 400-422.	2.4	85
27	A Gaussian Approximation Approach for Value of Information Analysis. <i>Medical Decision Making</i> , 2018, 38, 174-188.	2.4	36
28	Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. <i>Science</i> , 2018, 361, .	12.6	416
29	An Overview of R in Health Decision Sciences. <i>Medical Decision Making</i> , 2017, 37, 735-746.	2.4	73
30	Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis. <i>Pharmacoeconomics</i> , 2017, 35, 1073-1085.	3.3	9
31	Forecasting trends in disability in a super-aging society: Adapting the Future Elderly Model to Japan. <i>Journal of the Economics of Ageing</i> , 2016, 8, 42-51.	1.3	48
32	Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 1751-1757.	3.4	27
33	Some Health States Are Better Than Others. <i>Medical Decision Making</i> , 2016, 36, 927-940.	2.4	18
34	Cost-Effectiveness of a Statewide Campaign to Promote Aspirin Use for Primary Prevention of Cardiovascular Disease. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	10
35	Computing Expected Value of Partial Sample Information from Probabilistic Sensitivity Analysis Using Linear Regression Metamodeling. <i>Medical Decision Making</i> , 2015, 35, 584-595.	2.4	43
36	Linear Regression Metamodeling as a Tool to Summarize and Present Simulation Model Results. <i>Medical Decision Making</i> , 2013, 33, 880-890.	2.4	40

#	ARTICLE	IF	CITATIONS
37	Network Meta-analysis of Margin Threshold for Women With Ductal Carcinoma In Situ. Journal of the National Cancer Institute, 2012, 104, 507-516.	6.3	117
38	Including Indirect Medical Care Costs from Survivor Years of Life in Economic Evaluations. Pharmacoeconomics, 2011, 29, 173-174.	3.3	1